Medication and gene therapies for periprosthetic osteolysis / 中国组织工程研究

ABSTRACT

Aseptic loosening of the prosthesis due to periprosthetic osteolysis is one of the main causes that affect the service life following artificial joint replacement. The patient should undergo revision of artificial joints,but the surgery is of high difficulty,high risk and excessive cost,etc. Therefore,using nonsurgical technique to control artificial prosthesis osteolysis is an urgent and realistic task. Currently,the drug prevents osteolysis through inhibiting osteoclast bone resorption,responding to cytokines,and promoting bone formation. In addition,gene therapy and other treatments for osteolysis are under exploration.